Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot

Executive Summary

Meeting requests from sponsors that focus on safety prediction will also be prioritized.

Related Content

Complex Innovative Designs Pilot Likely Satisfies Industry's Disclosure Worries
US FDA's Complex Trial Design Pilot Might Be Handicapped By Disclosure Requirements
US FDA Offers Sponsors More Attention For Sharing Complex Innovative Trial Designs
Model-Informed Drug Development: A Risk Firms, Regulators Need To Embrace
PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts